Trumpp-Kallmeyer S[au] - Search Results

Year	Number of Results
1991	3
1992	1
1993	3
1994	1
1995	5
1996	2
1997	3
1998	3
1999	3
2000	1
2004	1
2022	0

1

Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site.

Heitz F, Holzwarth JA, Gies JP, Pruss RM, Trumpp-Kallmeyer S, Hibert MF, Guenet C. Heitz F, et al. Among authors: trumpp kallmeyer s. Eur J Pharmacol. 1999 Sep 10;380(2-3):183-95. doi: 10.1016/s0014-2999(99)00439-2. Eur J Pharmacol. 1999. PMID: 10513578

2

Functional architecture of vasopressin/oxytocin receptors.

Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chini B, Mahé E, Cotte N, Jard S, Manning M, Barberis C. Hibert M, et al. Among authors: trumpp kallmeyer s. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):589-96. doi: 10.3109/10799899909036674. J Recept Signal Transduct Res. 1999. PMID: 10071787 Review.

3

This is not a G protein-coupled receptor.

Hibert MF, Trumpp-Kallmeyer S, Hoflack J, Bruinvels A. Hibert MF, et al. Among authors: trumpp kallmeyer s. Trends Pharmacol Sci. 1993 Jan;14(1):7-12. doi: 10.1016/0165-6147(93)90106-t. Trends Pharmacol Sci. 1993. PMID: 8095116 Review.

4

G-Protein coupled receptors: models, mutagenesis, and drug design.

Bikker JA, Trumpp-Kallmeyer S, Humblet C. Bikker JA, et al. Among authors: trumpp kallmeyer s. J Med Chem. 1998 Jul 30;41(16):2911-27. doi: 10.1021/jm970767a. J Med Chem. 1998. PMID: 9685229 Review. No abstract available.

5

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E. Barvian M, et al. Among authors: trumpp kallmeyer s. J Med Chem. 2000 Nov 30;43(24):4606-16. doi: 10.1021/jm000271k. J Med Chem. 2000. PMID: 11101352

6

Three-dimensional models of neurotransmitter G-binding protein-coupled receptors.

Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Hibert MF, et al. Among authors: trumpp kallmeyer s. Mol Pharmacol. 1991 Jul;40(1):8-15. Mol Pharmacol. 1991. PMID: 1649965

7

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).

Polla MO, Tottie L, Nordén C, Linschoten M, Müsil D, Trumpp-Kallmeyer S, Aukrust IR, Ringom R, Holm KH, Neset SM, Sandberg M, Thurmond J, Yu P, Hategan G, Anderson H. Polla MO, et al. Among authors: trumpp kallmeyer s. Bioorg Med Chem. 2004 Mar 1;12(5):1151-75. doi: 10.1016/j.bmc.2003.12.039. Bioorg Med Chem. 2004. PMID: 14980627

8

Identification of a single residue responsible for agonist selectivity in the oxytocin-vasopressin receptors.

Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C. Chini B, et al. Among authors: trumpp kallmeyer s. Ann N Y Acad Sci. 1997 May 30;812:218-21. doi: 10.1111/j.1749-6632.1997.tb48181.x. Ann N Y Acad Sci. 1997. PMID: 9186749 No abstract available.

9

Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin.

Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C. Chini B, et al. Among authors: trumpp kallmeyer s. FEBS Lett. 1996 Nov 18;397(2-3):201-6. doi: 10.1016/s0014-5793(96)01135-0. FEBS Lett. 1996. PMID: 8955347 Free article.

10

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HD. Trumpp-Kallmeyer S, et al. J Med Chem. 1998 May 21;41(11):1752-63. doi: 10.1021/jm970634p. J Med Chem. 1998. PMID: 9599227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results